glp 1 agonist classification agonists drug class GLP-1 Receptor Agonists: An Alternative for Rapid-Acting Insulin? Classification of GLP 1R Agonists

Abstract Chronic kidney disease (CKD) remains a major public health problem, with type 2 diabetes and obesity representing key risk factors worldwide

69% have been using the medication for fewer than two years and 53% expect to discontinue use in less than two more years 77% who had discontinued a GLP-1 medication said they were satisfied with the weight loss they experienced, but 90% were on the drug for less than one year Primary barriers to continued use: 76% note side effects

Persistent nausea can create a general sense of malaise that patients describe as fatigue, while the physical effects of frequent vomiting or diarrhea can cause legitimate exhaustion

Glippy is available only in English, limiting its accessibility for non-English-speaking GLP-1 users